[ 1 ] Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380(15):1450–62. link1

[ 2 ] Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšic´ M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391 (10125):1023–75. link1

[ 3 ] Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2(1):16018. link1

[ 4 ] Cancer stat facts: liver and and intrahepatic bile duct cancer [Internet]. Washington, DC: National Cancer Institute; c2020 [cited 2020 Jul 6]. Available from: https://seer.cancer.gov/statfacts/html/livibd.html.

[ 5 ] Van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KMJ, Klümpen HJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J Hepatol 2015;63(5):1156–63. link1

[ 6 ] Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68(2):723–50. link1

[ 7 ] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69 (1):182–236. link1

[ 8 ] Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 2019;157(1):54–64. link1

[ 9 ] Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MAM, et al. Metaanalysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30(1):37–47. link1

[10] Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154 (6):1706–18.e1. link1

[11] Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013;19(3):339–46. link1

[12] Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014;23(1):144–53. link1

[13] FDA grants Breakthrough Device Designation for Roche’s Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma [Internet]. Basel: Roche; c2021 [cited 2020 Jul 30]. Available from: https://www. roche.com/media/releases/med-cor-2020-03-04.htm.

[14] Wen L, Li J, Guo H, Liu X, Zheng S, Zhang D, et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. Cell Res 2015;25(11):1250–64. link1

[15] Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017;16(11):1155–61. link1

[16] Kisiel JB, Dukek BA, VSR Kanipakam R, Ghoz HM, Yab TC, Berger CK, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology 2019;69(3):1180–92. link1

[17] Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut 2019;68 (12):2195–205. link1

[18] Tao K, Bian Z, Zhang Q, Guo X, Yin C, Wang Y, et al. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma. EBioMedicine 2020;56:102811. link1

[19] Jiang P, Sun K, Tong YK, Cheng SH, Cheng THT, Heung MMS, et al. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc Natl Acad Sci USA 2018;115 (46):E10925–33. link1

[20] Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29(36):4781–8. link1

[21] Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS ONE 2014;9(9):e107986. link1

[22] Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested casecontrol study. Lancet Oncol 2015;16(7):804–15. link1

[23] Yuan W, Sun Y, Liu L, Zhou B, Wang S, Gu D. Circulating lncRNAs serve as diagnostic markers for hepatocellular carcinoma. Cell Physiol Biochem 2017;44(1):125–32. link1

[24] Liu J, Tang W, Budhu A, Forgues M, Hernandez MO, Candia J, et al. A viral exposure signature defines early onset of hepatocellular carcinoma. Cell 2020;182(2):317–28.e10. link1

[25] Qu C, Wang Y, Wang P, Chen K, Wang M, Zeng H, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci USA 2019;116(13):6308–12. link1

[26] Chen L, Abou-Alfa GK, Zheng B, Liu JF, Bai J, Du LT, et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res 2021;31(5):589–92. link1

[27] Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017;545(7655):446–51. link1

[28] Von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut 2020;69 (11):2025–34. link1

[29] Labgaa I, Villacorta-Martin C, D’Avola D, Craig AJ, von Felden J, Martins-Filho SN, et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018;37 (27):3740–52. link1

[30] Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology 2015;61(6):1945–56. link1

[31] Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020;31(6):745–59. link1

[32] Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324(5929):930–5. link1

[33] Song CX, Yin S, Ma L, Wheeler A, Chen Y, Zhang Y, et al. 5- hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res 2017;27(10):1231–42. link1

[34] Li W, Zhang X, Lu X, You L, Song Y, Luo Z, et al. 5-hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res 2017;27(10):1243–57. link1

[35] Xu H, Zhu X, Xu Z, Hu Y, Bo S, Xing T, et al. Non-invasive analysis of genomic copy number variation in patients with hepatocellular carcinoma by next generation DNA sequencing. J Cancer 2015;6(3):247–53. link1

[36] Ivanov M, Baranova A, Butler T, Spellman P, Mileyko V. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics 2015;16(Suppl 13):S1. link1

[37] Jiang P, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VS, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci USA 2015;112(11):E1317–25. link1

[38] Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 2019;570 (7761):385–9. link1

[39] Jiang P, Sun K, Peng W, Cheng SH, Ni M, Yeung PC, et al. Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation. Cancer Discov 2020;10(5):664–73. link1

[40] Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016;164(1–2):57–68. link1

[41] Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet 2016;48(10):1273–8. link1

[42] Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359(6378):926–30. link1

[43] Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020;369(6499):eabb9601. link1

[44] Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93(14):1054–61. link1